Phase I study of recombinant human interleukin-18 (IL-18) in combination with ofatumumab after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoma.

Michael J. Robertson,Lijun Ni,Jill Weisenbach,David Pelloso,Nagendra K Prasad

Phase I study of recombinant human interleukin-18 (IL-18) in combination with ofatumumab after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoma.

2016

Michael J. Robertson
Lijun Ni
Jill Weisenbach
David Pelloso
Nagendra K Prasad

e19066Background: IL-18 is an immunostimulatory cytokine that is well-tolerated in combination with the CD20 mAb rituximab. Ofatumumab is a CD20 mAb that is more potent than rituximab in preclinica...

Keywords:

Ofatumumab
Lymphoma
Interleukin 18
Immunology
Recombinant DNA
Pathology
Medicine
Peripheral Blood Stem Cell Transplantation
Rituximab
CD20
Cytokine
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations